Key result
Allogeneic mesenchymal stem cells have proven safe in initial phase I/II trials for acute myocardial infarction and chronic heart failure, though long-term safety, efficacy, and immunogenicity remain to be established.
Why the study?
Does allogeneic mesenchymal stem cell therapy improve cardiac function and safety in patients with myocardial infarction or chronic heart failure?
Population
Patients with myocardial infarction (MI) or chronic heart failure (CHF), as well as preclinical animal models.
Comparison
Allogeneic mesenchymal stem cells administered… vs Autologous stem cells, syngeneic stem cells, or…
Design
Review
Authors
Loading...
Encourages larger efficacy trials of allogeneic mesenchymal stem cells in heart failure; leaves open long-term safety and immunogenicity.
Does allogeneic mesenchymal stem cell therapy improve cardiac function and safety in patients with myocardial infarction or chronic heart failure?
Allogeneic mesenchymal stem cells offer a promising 'off-the-shelf' therapy for cardiac repair after myocardial infarction, though their potential to induce immune rejection requires further investigation in ongoing trials.
Vassalli et al. (2011) conducted a review in Myocardial infarction. Allogeneic mesenchymal stem cells was evaluated. Allogeneic mesenchymal stem cells have proven safe in initial phase I/II trials for acute myocardial infarction and chronic heart failure, though long-term safety, efficacy, and immunogenicity remain to be established.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: